Emerging Role of IL-17 in Atherosclerosis

被引:88
作者
Chen, Shuang
Crother, Timothy R.
Arditi, Moshe [1 ]
机构
[1] Cedars Sinai Med Ctr, Dept Pediat, Div Pediat Infect Dis & Immunol, Burns & Allen Res Inst, Los Angeles, CA 90048 USA
关键词
Atherosclerosis; IL-17; Innate and adaptive immunity; REGULATORY T-CELLS; INTERLEUKIN-17; FAMILY; INTERFERON-GAMMA; TH17; CELLS; REDUCED ATHEROSCLEROSIS; ALTERNATIVE PATHWAY; TGF-BETA; DEFICIENT; DIFFERENTIATION; LYMPHOCYTES;
D O I
10.1159/000314626
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The IL-23-IL-17 axis is emerging as a critical regulatory system that bridges the innate and adaptive arms of the immune system. Th17 cells have been linked to the pathogenesis of several chronic inflammatory and autoimmune diseases. However, the role of Th17 cells and IL-17 in various stages of atherogenesis remains poorly understood and is only beginning to be elucidated. While IL-17 is a predominantly proinflammatory cytokine, it has a pleiotropic function and it has been implicated both as an instigator in the pathogenesis of several inflammatory disorders as well as being protective in certain inflammatory disease models. Therefore, it is not surprising that the current literature is conflicting on the role of IL-17 during atherosclerotic lesion development. Various approaches have been used by several groups to discern the involvement of IL-17 in atherosclerosis. While one study found that IL-17 is protective against atherosclerosis, several other recent studies have suggested that IL-17 plays a pro-atherogenic role. Thus, the function of IL-17 remains controversial and awaits more direct studies to address the issue. In this review, we will highlight all the latest studies involving IL-17 and atherosclerosis, including both clinical and experimental research. Copyright (C) 2010 S. Karger AG, Basel
引用
收藏
页码:325 / 333
页数:9
相关论文
共 101 条
[21]   TH 17 cells in development:: an updated view of their molecular identity and genetic programming [J].
Dong, Chen .
NATURE REVIEWS IMMUNOLOGY, 2008, 8 (05) :337-348
[22]   Expression of toll-like receptors in human atherosclerotic lesions - A possible pathway for plaque activation [J].
Edfeldt, K ;
Swedenborg, J ;
Hansson, GK ;
Yan, ZQ .
CIRCULATION, 2002, 105 (10) :1158-1161
[23]   Interleukin-17 and Interferon-γ Are Produced Concomitantly by Human Coronary Artery-Infiltrating T Cells and Act Synergistically on Vascular Smooth Muscle Cells [J].
Eid, Raymond E. ;
Rao, Deepak A. ;
Zhou, Jing ;
Lo, Sheng-Fu L. ;
Ranjbaran, Hooman ;
Gallo, Amy ;
Sokol, Seth I. ;
Pfau, Steven ;
Pober, Jordan S. ;
Tellides, George .
CIRCULATION, 2009, 119 (10) :1424-1432
[24]   Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice [J].
Elhage, R ;
Jawien, J ;
Rudling, M ;
Ljunggren, HG ;
Takeda, K ;
Akira, S ;
Bayard, F ;
Hansson, GK .
CARDIOVASCULAR RESEARCH, 2003, 59 (01) :234-240
[25]   Inhibition of IL-17A Attenuates Atherosclerotic Lesion Development in ApoE-Deficient Mice [J].
Erbel, Christian ;
Chen, Lili ;
Bea, Florian ;
Wangler, Susanne ;
Celik, Sultan ;
Lasitschka, Felix ;
Wang, Ying ;
Boeckler, Dittmar ;
Katus, Hugo A. ;
Dengler, Thomas J. .
JOURNAL OF IMMUNOLOGY, 2009, 183 (12) :8167-8175
[26]   IL-25 induces IL-4 IL-5, and IL-13 and Th2-associated pathologies in vivo [J].
Fort, MM ;
Cheung, J ;
Yen, D ;
Li, J ;
Zurawski, SM ;
Lo, S ;
Menon, S ;
Clifford, T ;
Hunte, B ;
Lesley, R ;
Muchamuel, T ;
Hurst, SD ;
Zurawski, G ;
Leach, MW ;
Gorman, DM ;
Rennick, DM .
IMMUNITY, 2001, 15 (06) :985-995
[27]   The IL-17 cytokine family [J].
Gaffen, Sarah L. ;
Kramer, Jill M. ;
Yu, Jeffrey J. ;
Shen, Fang .
INTERLEUKINS, 2006, 74 :255-282
[28]  
Grainger DJ, 2000, J CELL SCI, V113, P2355
[29]   IFN-gamma potentiates atherosclerosis in apoE knock-out mice [J].
Gupta, S ;
Pablo, AM ;
Jiang, XC ;
Wang, N ;
Tall, AR ;
Schindler, C .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (11) :2752-2761
[30]   Innate and adaptive immunity in the pathogenesis of atherosclerosis [J].
Hansson, GK ;
Libby, P ;
Schönbeck, U ;
Yan, ZQ .
CIRCULATION RESEARCH, 2002, 91 (04) :281-291